• Skip to primary navigation
  • Skip to main content

Destum Partners

Bridging the Gap Between Science and Business

  • HOME
  • SERVICES
    • ADVISORY PRACTICES
    • CONSULTING PRACTICES
  • SUCCESS
    • ADVISORY
    • CONSULTING
  • ABOUT
  • NEWS & EVENTS
  • CONTACT

June 11, 2018 By

HC2 Completes Sale of Pansend Life Sciences Portfolio Company Benevir Biopharm to Janssen Biotech, Inc. for up to $1.04 Billion

New York | June 11, 2018 – HC2 Holdings, Inc. (“HC2”) (NYSE:HCHC), a diversified holding company, announced today that it has completed the sale of BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, to Janssen Biotech, Inc. (“Janssen”).

In conjunction with the closing of the transaction, Janssen made an upfront cash payment of $140 million, of which HC2 received approximately $73 million. In addition, assuming no pending or unresolved indemnified claims, HC2 will receive approximately $10 million being held in escrow for fifteen months. Inclusive of additional contingent payments of up to $900 million based on achievement of certain predetermined milestones, the total amount of all payments for this transaction could exceed $1 billion if all milestones are met.

Read More >

Filed Under: NEWS

admin

WORK WITH US

Destum Partners serves an exclusive clientele with a shared passion for business and science. Our Clients range from multinational fortune 500 companies to midsized and early stage privately held companies. We truly have a global reach, with Clients in our portfolio based in Asia, Europe and the Americas.

    Copyright © 2025 · Destum Partners · All Rights Reserved.